Kristine M Ball Net Worth

The estimated Net Worth of Kristine M Ball is at least $100 Thousand dollars as of 11 December 2019. Kristine Ball owns over 80,300 units of Atreca Inc stock worth over $7,227 and over the last 21 years Kristine sold BCEL stock worth over $92,969.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Kristine Ball BCEL stock SEC Form 4 insiders trading

Kristine has made over 3 trades of the Atreca Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Kristine exercised 80,300 units of BCEL stock worth $7,227 on 11 December 2019.

The largest trade Kristine's ever made was exercising 80,300 units of Atreca Inc stock on 11 December 2019 worth over $7,227. On average, Kristine trades about 7,206 units every 452 days since 2003. As of 11 December 2019 Kristine still owns at least 80,300 units of Atreca Inc stock.

You can see the complete history of Kristine Ball stock trades at the bottom of the page.

What's Kristine Ball's mailing address?

Kristine's mailing address filed with the SEC is C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS, CA, 94070.

Insiders trading at Atreca Inc

Over the last 5 years, insiders at Atreca Inc have traded over $4,571,843 worth of Atreca Inc stock and bought 6,001 units worth $76,740 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro..., and Harbor Master Investors (Ca.... On average, Atreca Inc executives and independent directors trade stock every 20 days with the average trade being worth of $991. The most recent stock trade was executed by John A Orwin on 11 April 2024, trading 1 units of BCEL stock currently worth $0.

What does Atreca Inc do?

atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/

Complete history of Kristine Ball stock trades at Exelixis Inc, Menlo Therapeutics, and Atreca Inc

Atreca Inc executives and stock owners

Atreca Inc executives and other stock owners filed with the SEC include:

• John A. Orwin,
  Pres, CEO & Director
• Herbert C. Cross,
  Chief Financial Officer
• Dr. Stephen Gould Ph.D.,
  Chief Scientific Officer
• Dr. Jonathan Benjamin M.D., Ph.D.,
  Sr. VP of Clinical Research
• Dr. Daniel Emerling,
  Sr. VP of Research
• Courtney J. Phillips J.D.,
  Gen. Counsel & Corp. Sec.
• Dr. Yann Chong Tan,
  Chief Technologist
• Dr. Tito A. Serafini Ph.D.,
  Founder, Chief Strategy Officer & Director
• Bros. Advisors Lpbaker Juli...,
  
• Kristine M Ball,
  Director
• David L. Lacey,
  Director
• Philippe C Bishop,
  Chief Medical Officer
• Tito Serafini,
  
• Franklin M Berger,
  Director
• Brian G Atwood,
  Director
• Lawrence Steinman,
  Director
• William Hewitt Robinson,
  Director
• & Melinda Gates Foundation ...,
  
• Group, Llc Green Jeremy Red...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Bros. Advisors Lp Baker Bro...,
  
• Guy Cavet,
  Chief Technical Officer
• Norman Michael Greenberg,
  Chief Scientific Officer
• Lindsey Rolfe,
  Director
• Herb Cross,
  Chief Financial Officer
• Lisa Lynn Decker,
  Chief Business Officer
• Stacey Ma,
  Director
• Stephen R Brady,
  Director
• Stephen E Gould,
  Chief Scientific Officer
• Phillips Courtney,
  GENERAL COUNSEL & SECRETARY
• John A Orwin,
  PRESIDENT & CEO